%0 Journal Article
%T Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review.
%A Ma P
%A Jiang Y
%A Zhao G
%A Wang W
%A Xing S
%A Tang Q
%A Miao H
%A Fang H
%A Sun C
%A Fang Y
%A Jiang N
%A Huang H
%A Wang S
%A Xie X
%A Li N
%J Eur J Cancer
%V 209
%N 0
%D 2024 Sep 10
%M 39067370
%F 10.002
%R 10.1016/j.ejca.2024.114224
%X T-cell receptor therapy (TCR-T) has demonstrated efficacy, durability, and safety advantages in certain solid tumors (such as human papillomavirus-related tumors, synovial sarcoma, and melanoma). This study aimed to provide careful considerations for developing TCR-T for solid tumors. Therefore, in this review, we have summarized the current clinical application, advantage of TCR-T modalities and explored efficacy/safety-related parameters, particularly avidity, pharmacokinetics/pharmacodynamics, and indications, for solid tumors. Furthermore, we have investigated critical factors related to avidity, including antigen selection, T-cell receptor acquisition, optimization, and co-receptor engagement. Moreover, we have re-examined the expression of tumor antigens for a potentially higher coverage rate of solid tumors based on the current RNA-seq datasets. Finally, we have discussed the current limitations and future directions of TCR-Ts.